Normal view

There are new articles available, click to refresh the page.
Yesterday — 20 September 2024Main stream

David Schwimmer ‘Surprised’ to Hear Matthew Perry Once Praised His ‘Friends’ Comedy Skills: He ‘Was Reserved With Me. He Would Not Say That to Me’

19 September 2024 at 23:06
David Schwimmer appeared on the “Origins with Cush Jumbo” podcast (via People) and was surprised to hear the host talk about a conversation she once had with Matthew Perry in which the late actor praised Schwimmer’s physical comedy chops. Perry and Jumbo starred together on a season of “The Good Fight,” while Perry and Schwimmer spent 10 seasons […]

Before yesterdayMain stream

Trial Date Set for Doctor and ‘Ketamine Queen’ Linked to Matthew Perry Case

4 September 2024 at 00:12
An official court date has been set for the trial of alleged “Ketamine Queen” Jasveen Sangha and Dr. Salvador Plasencia, who are accused of supplying Matthew Perry with the drugs that led to his overdose on Oct. 28, 2023. If found guilty, the pair could face several decades in prison. When this article was published, […]

Ketamine pills for depression show positive results in trial—but with caveats

By: Beth Mole
25 June 2024 at 20:18
Ketamine pills for depression show positive results in trial—but with caveats

Enlarge (credit: Getty | RJ Sangosti)

After an MDMA therapy for post-traumatic stress disorder dramatically failed to impress Food and Drug Administration advisers earlier this month, researchers are moving forward with another psychedelic—a slow-release oral dose of the hallucinogenic drug ketamine—as a therapy for treatment-resistant depression.

In a mid-stage, randomized, placebo-controlled clinical trial, researchers tested slow-release ketamine pills, taken twice weekly. The trial, sponsored by New Zealand-based Douglas Pharmaceuticals, found ketamine to be safe compared with placebo. At the trial's highest dose, the treatment showed some efficacy against depression in patients who had previously tried an average of nearly five antidepressants without success, according to the results published Monday in Nature Medicine.

But the Phase II trial, which started with 231 participants, indicated that the pool of patients who may benefit from the treatment could be quite limited. The researchers behind the trial chose an unusual "enrichment" design to test the depression treatment. This was intended to thwart the high failure rates generally seen in trials for depression treatments, even in patients without treatment-resistant cases. But even after selecting patients who initially responded to ketamine, 59.5 percent of the enriched participants still dropped out of the trial before its completion, largely due to a lack of efficacy.

Read 16 remaining paragraphs | Comments

❌
❌